TRAVASE
LOE ApproachingNDATOPICALOINTMENTPriority Review
Approved
Jun 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVASE is a topical ointment small-molecule product approved by Abbott in 1969 for dermatological indications. The specific mechanism of action and therapeutic target are not publicly detailed in available data. This is a legacy product with established clinical utility in wound care or similar topical applications.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30); limited linked job openings suggest a mature, potentially right-sized team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRAVASE offers minimal active career growth opportunity, with zero linked job openings. Working on this product means supporting a legacy brand in its final revenue-generating years, focusing on cost management, market defense, and transition planning rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on TRAVASE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.